<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02087475</url>
  </required_header>
  <id_info>
    <org_study_id>SAH 5010 CRC</org_study_id>
    <nct_id>NCT02087475</nct_id>
  </id_info>
  <brief_title>Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin</brief_title>
  <official_title>Randomized Open-label Phase III Study Comparing Perioperative FOLFIRI Versus Adjuvant FOLFIRI in Resectable Advanced Colorectal Cancer Failed to Oxaliplatin-containing Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer (CRC) is one of the most leading causes of cancer death in China. Although
      multiple treatment modalities including surgery, radiotherapy and chemotherapy have been
      developed, the prognosis of advanced CRC still remains poor. While around 30% of resectable
      advanced CRC could be cured. This study is designed to compare perioperative FOLFIRI versus
      adjuvant FOLFIRI in resectable advanced CRC who exposed to oxaliplatin in open-label, phase
      III mode.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress Free Survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 Resection Rate</measure>
    <time_frame>6 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>3 Year</time_frame>
    <description>Adverse events grade that greater than 3 is considered secondary endpoint, according to the Common Terminology Criteria for Adverse Events Version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality</measure>
    <time_frame>3 Years</time_frame>
    <description>EORTC QoL Questionaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Effects of Chemotherapy</condition>
  <condition>Surgery</condition>
  <condition>Metastasis</condition>
  <condition>Local Neoplasm Recurrence</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant therapy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFIRI * 6 cycles +/- radiotherapy -&gt; surgery -&gt; FOLFIRI * 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant therapy arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgery -&gt; FOLFIRI * 12 cycles +/- radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Neoadjuvant therapy arm</arm_group_label>
    <arm_group_label>Adjuvant therapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <arm_group_label>Neoadjuvant therapy arm</arm_group_label>
    <arm_group_label>Adjuvant therapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Local radiotherapy</intervention_name>
    <arm_group_label>Neoadjuvant therapy arm</arm_group_label>
    <arm_group_label>Adjuvant therapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>R0 resection</intervention_name>
    <arm_group_label>Neoadjuvant therapy arm</arm_group_label>
    <arm_group_label>Adjuvant therapy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age:18-80

          -  ECOG score: 0 or 1

          -  Histological confirmed of Colorectal Adenocarcinoma

          -  History of exposure to oxaliplatin

          -  With local recurrent or metastatic focus

          -  Tumor resectable confirmed by at less 3 hepatobiliary surgeon

          -  Informed content acquired

        Exclusion Criteria:

          -  History of Exposure to Irinotecan

          -  Received surgery in recently 4 weeks or did not recover from surgery

          -  Other history of cancer in recent 5 years

          -  Fluorouracil allergy or dihydropyrimidine dehydrogenase defect

          -  Women with potential pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Lan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Xiao, MD</last_name>
    <phone>+8613711114566</phone>
    <email>xiao_jian@139.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The 6th Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Xiao, MD</last_name>
      <phone>+8613711114566</phone>
      <email>xiao_jian@139.com</email>
    </contact>
    <investigator>
      <last_name>Jian Xiao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2014</study_first_submitted>
  <study_first_submitted_qc>March 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2014</study_first_posted>
  <last_update_submitted>March 12, 2014</last_update_submitted>
  <last_update_submitted_qc>March 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Lan Ping</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Recurrence, Local</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

